Munehiro Ito

702 total citations
14 papers, 541 citations indexed

About

Munehiro Ito is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology. According to data from OpenAlex, Munehiro Ito has authored 14 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 2 papers in Hematology. Recurrent topics in Munehiro Ito's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Munehiro Ito is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Munehiro Ito collaborates with scholars based in Japan and United States. Munehiro Ito's co-authors include Daichi Fujimoto, Keisuke Tomii, Yuki Sato, Atsushi Nakagawa, Kojiro Otsuka, Kazuma Nagata, Shunsuke Teraoka, Takeshi Morimoto, Keiichiro Uehara and Yukihiro Imai and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Munehiro Ito

14 papers receiving 540 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Munehiro Ito Japan	8	481	317	81	54	31	14	541
John A. Kosteva United States	6	435 0.9×	204 0.6×	77 1.0×	48 0.9×	52 1.7×	12	496
Balazs Medgyasszay Spain	5	592 1.2×	429 1.4×	93 1.1×	49 0.9×	43 1.4×	7	641
Virginia Palomar Coloma France	4	421 0.9×	190 0.6×	118 1.5×	65 1.2×	48 1.5×	5	481
Kyoji Tsurumi Japan	6	492 1.0×	232 0.7×	103 1.3×	43 0.8×	14 0.5×	11	531
Keisuke Terayama Japan	6	491 1.0×	230 0.7×	103 1.3×	42 0.8×	13 0.4×	10	531
Yutaka Domeki Japan	6	491 1.0×	229 0.7×	103 1.3×	41 0.8×	13 0.4×	10	529
Eriko Murakami Japan	6	409 0.9×	194 0.6×	74 0.9×	53 1.0×	14 0.5×	15	459
Tomoiki Aiba Japan	7	496 1.0×	235 0.7×	107 1.3×	43 0.8×	13 0.4×	18	544
Yan-Ping Mao China	2	364 0.8×	125 0.4×	94 1.2×	52 1.0×	18 0.6×	2	417
Elizabeth Panora United States	5	339 0.7×	165 0.5×	52 0.6×	33 0.6×	16 0.5×	7	388

Countries citing papers authored by Munehiro Ito

Since Specialization

Citations

This map shows the geographic impact of Munehiro Ito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Munehiro Ito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Munehiro Ito more than expected).

Fields of papers citing papers by Munehiro Ito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Munehiro Ito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Munehiro Ito. The network helps show where Munehiro Ito may publish in the future.

Co-authorship network of co-authors of Munehiro Ito

This figure shows the co-authorship network connecting the top 25 collaborators of Munehiro Ito. A scholar is included among the top collaborators of Munehiro Ito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Munehiro Ito. Munehiro Ito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Shimoi, Tatsunori, Yuki Kojima, T. Yamanaka, et al.. (2024). Abstract PO3-15-12: Expression and co-expression patterns of TROP2 and HER2 in breast cancer: implications for bispecific antibody-drug conjugate therapy. Cancer Research. 84(9_Supplement). PO3–15. 2 indexed citations

Kitadai, Rui, Tatsunori Shimoi, Hitomi Sumiyoshi Okuma, et al.. (2024). Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. Breast Cancer. 31(6). 1037–1045. 2 indexed citations

Ito, Munehiro, Shintaro Kanda, Tatsuya Yoshida, et al.. (2020). Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient. Lung Cancer. 146. 362–365. 7 indexed citations

Ito, Munehiro, Yutaka Fujiwara, Takashi Kubo, et al.. (2020). Clonal Hematopoiesis From Next Generation Sequencing of Plasma From a Patient With Lung Adenocarcinoma: A Case Report. Frontiers in Oncology. 10. 113–113. 3 indexed citations

Ito, Munehiro, Ken Kato, Shun Yamamoto, et al.. (2020). Loss of body weight during neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil as predictive of poor survival of patients with esophageal squamous cell carcinoma.. Journal of Clinical Oncology. 38(4_suppl). 371–371. 4 indexed citations

Fujiwara, Satoru, Naoya Mimura, Hajime Yoshimura, et al.. (2019). Elevated Adenosine Deaminase Levels in the Cerebrospinal Fluid in Immune Checkpoint Inhibitor-induced Autoimmune Encephalitis. Internal Medicine. 58(19). 2871–2874. 16 indexed citations

Fujimoto, Daichi, Yuki Sato, Takeshi Morimoto, et al.. (2018). Programmed Cell Death Ligand 1 Expression in Non–Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study. Clinical Lung Cancer. 19(5). e667–e673. 11 indexed citations

Kawachi, Hayato, Daichi Fujimoto, Takeshi Morimoto, et al.. (2018). Clinical Characteristics and Prognosis of Patients With Advanced Non–Small-cell Lung Cancer Who Are Ineligible for Clinical Trials. Clinical Lung Cancer. 19(5). e721–e734. 26 indexed citations

Fujimoto, Daichi, Keiichiro Uehara, Yuki Sato, et al.. (2017). Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Scientific Reports. 7(1). 11373–11373. 68 indexed citations

10.

Fujimoto, Daichi, Takeshi Morimoto, Jiro Ito, et al.. (2017). A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. Lung Cancer. 111. 1–5. 58 indexed citations

11.

Fujimoto, Daichi, Yuki Sato, Keiichiro Uehara, et al.. (2017). Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(3). 377–386. 44 indexed citations

12.

Teraoka, Shunsuke, Daichi Fujimoto, Takeshi Morimoto, et al.. (2017). Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. Journal of Thoracic Oncology. 12(12). 1798–1805. 293 indexed citations

13.

Fujimoto, Daichi, et al.. (2017). Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature. Oncotarget. 8(29). 48521–48524. 6 indexed citations

14.

Teraoka, Shunsuke, Daichi Fujimoto, Munehiro Ito, et al.. (2016). Intolarence of pirfenidone and its associated factors in the real world. PA786–PA786. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact